Our lead pipeline candidate is CNTX-4975, a highly potent, ultrapure, synthetic form of capsaicin (a derivative of the chili plant), called trans-capsaicin, which is the first and only, patented capsaicin designed to be administered via injection into the site of pain (Company Pipeline, Centrexion Therapeutics, MAY 3, 2016, View Source [SID:1234511816]). CNTX-4975 was developed in a research lab at The Johns Hopkins School of Medicine by co-founder and CSO, James Campbell, M.D. It is being evaluated for the treatment of osteoarthritis (OA) pain of the knee in humans and canines, as well as in patients with Morton’s neuroma, a painful foot condition. CNTX-4975 is injected directly into the affected knee or neuroma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Centrexion harnessed the natural analgesic power of capsaicin to develop its exclusive injectable therapy designed to provide fast-acting, long-lasting and targeted pain relief.
It works by selectively targeting the capsaicin receptor (also known as TRPV1) that inactivates the nerve fibers transmitting pain signals to the brain – a therapeutic affect that can last for months until the nerve fiber regenerates. Through its targeted delivery process and method of action, CNTX-4975 manages pain without disrupting other nerve functions.